Back
Top 51%
12.4%
Top 0.2%
12.4%
#1
11.5%
Top 12%
11.5%
Top 0.7%
9.4%
Top 0.4%
6.7%
Top 4%
4.0%
Top 0.9%
2.9%
Top 10%
2.0%
Top 79%
2.0%
Top 10%
1.4%
Top 2%
1.0%
Top 16%
1.0%
Top 10%
0.7%
Top 29%
0.7%
Top 13%
0.7%
Top 20%
0.7%
Comparative Effectiveness and Cardiovascular Outcomes of Infliximab reference product and Biosimilars in Patients with Inflammatory Bowel Disease
2026-01-27
gastroenterology
Title + abstract only
View on medRxiv
Show abstract
BackgroundAnti-tumor necrosis factor (anti-TNF), particularly infliximab, have transformed inflammatory bowel disease (IBD) management, but their high cost imposes a significant economic burden. Infliximab biosimilars were introduced to reduce the unmet needs. Despite the approval of infliximab biosimilars, real-world evidence of cardiovascular safety and effectiveness of infliximab biosimilars is lacking among patients with IBD. In this trial emulation, we compared the effectiveness and cardiov...
Predicted journal destinations
1
PLOS ONE
1737 training papers
2
American Journal of Gastroenterology
15 training papers
3
Gut
17 training papers
4
BMJ Open
553 training papers
5
Vaccines
131 training papers
6
Frontiers in Medicine
99 training papers
7
Journal of Clinical Medicine
77 training papers
8
Gut Microbes
15 training papers
9
BMC Medicine
155 training papers
10
Scientific Reports
701 training papers
11
PLOS Medicine
95 training papers
12
Frontiers in Pharmacology
27 training papers
13
Cureus
64 training papers
14
Vaccine
140 training papers
15
JAMA Network Open
125 training papers
16
Frontiers in Immunology
140 training papers
17
Journal of Medical Internet Research
81 training papers